从抗精神病多药治疗转为单药治疗可减少副作用

The Brown University Psychopharmacology Update Pub Date : 2024-11-26 DOI:10.1002/pu.31250

{"title":"从抗精神病多药治疗转为单药治疗可减少副作用","authors":"","doi":"10.1002/pu.31250","DOIUrl":null,"url":null,"abstract":"Inpatients with schizophrenia who switched from antipsychotic polypharmacy to monotherapy experienced significantly reduced side effects, including extrapyramidal symptoms and metabolic effects, an open-label trial has found. The vast majority of patients in the study's switch group stopped taking a first-generation antipsychotic and continued on their second-generation drug. Study results were published online Sept. 16, 2024, in Schizophrenia Research.","PeriodicalId":22275,"journal":{"name":"The Brown University Psychopharmacology Update","volume":"36 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Switch from antipsychotic polypharmacy to monotherapy reduces side effects\",\"authors\":\"\",\"doi\":\"10.1002/pu.31250\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Inpatients with schizophrenia who switched from antipsychotic polypharmacy to monotherapy experienced significantly reduced side effects, including extrapyramidal symptoms and metabolic effects, an open-label trial has found. The vast majority of patients in the study's switch group stopped taking a first-generation antipsychotic and continued on their second-generation drug. Study results were published online Sept. 16, 2024, in Schizophrenia Research.\",\"PeriodicalId\":22275,\"journal\":{\"name\":\"The Brown University Psychopharmacology Update\",\"volume\":\"36 1\",\"pages\":\"1-6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-11-26\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Brown University Psychopharmacology Update\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/pu.31250\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Brown University Psychopharmacology Update","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/pu.31250","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

一项开放标签试验发现，精神分裂症住院患者从服用多种抗精神病药物转为单药治疗后，副作用明显减少，包括锥体外系症状和代谢影响。在该研究的转换组中，绝大多数患者停止服用第一代抗精神病药物，继续服用第二代药物。研究结果于2024年9月16日在线发表在《精神分裂症研究》（Schizophrenia Research）杂志上。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Switch from antipsychotic polypharmacy to monotherapy reduces side effects

Inpatients with schizophrenia who switched from antipsychotic polypharmacy to monotherapy experienced significantly reduced side effects, including extrapyramidal symptoms and metabolic effects, an open-label trial has found. The vast majority of patients in the study's switch group stopped taking a first-generation antipsychotic and continued on their second-generation drug. Study results were published online Sept. 16, 2024, in Schizophrenia Research.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

The Brown University Psychopharmacology Update

自引率

0.00%

发文量